Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a cytosolic pattern recognition receptor that serves as a primary sensor for bacterial peptidoglycan fragments, specifically muramyl dipeptide (MDP). Upon ligand binding, NOD2 undergoes a conformational change and oligomerization, recruiting the kinase RIPK2 to activate the NF-kappaB and MAP kinase pathways, which are essential for the innate immune response and the production of antimicrobial peptides. Genetic variations in NOD2 are highly significant in clinical medicine; loss-of-function mutations are strongly linked to an increased risk of Crohn's disease due to impaired mucosal immunity, while gain-of-function mutations cause Blau syndrome, a systemic granulomatous disorder. In the context of drug development, NOD2 is targeted by agonists like mifamurtide to enhance immune responses in oncology, and by small-molecule inhibitors designed to treat chronic inflammatory conditions. Beyond its role in inflammation, NOD2 also regulates autophagy and maintains the integrity of the intestinal barrier, making it a central regulator of host-microbe interactions. The protein's structure, featuring N-terminal CARD domains, a central NOD domain, and C-terminal leucine-rich repeats, provides multiple sites for therapeutic intervention and allosteric modulation.
NOD2 agonists bind to the C-terminal leucine-rich repeat domain, triggering a conformational change that allows the nucleotide-binding domain to oligomerize and the N-terminal CARD domains to recruit RIPK2, ultimately activating NF-kB and MAPK pathways to induce pro-inflammatory gene expression. Inhibitors target these protein-protein interactions or the ATP-binding site to dampen excessive inflammatory signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (NOD2).